STAT Plus: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’
With Humira biosimilars taking over the market, the PBM found a crafty way to keep as much money as possible.
Read The StoryBusiness
STAT has a blockbuster team of reporters covering every major health care industry in the United States, from pharma, biotech, hospitals, insurance, health tech to medical devices.
They focus on breaking news, investigations, and features about the ways money is shaping medicine, from early investments in research to pricing and regulatory decisions that shape a company’s finances.
To get the latest health care business news delivered to your inbox, sign up for our free, weekly newsletter on the business of health care, STAT’s Health Care Inc.. Or you can sign up for our daily newsletter on biotech, The Readout, or our twice-weekly Health Tech newsletter. And subscribe to STAT+ for inside intelligence on the life sciences, health policy, health tech developments, and biopharma.
STAT Plus: As AI marches into medicine, investors eye security, privacy startups
STAT Plus: What happens when an approved drug doesn’t work?
STAT Plus: UnitedHealth is on a buying spree of outpatient surgery centers
Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
All Coverage
advertisement
